Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 19/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18764771 | 0.99 | SLC40A1 (0.61) | SLC40A1ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL29505664 | 0.99 | SLC40A1 (0.61) | SLC40A1ADORA2AADORA1 | |
| SCHEMBL31738698 | 0.92 | SLC40A1 (0.65) | SLC40A1 | |
| SCHEMBL18792413 | 0.92 | SLC40A1 (0.65) | SLC40A1 | |
| Hydrochloric Acid SCHEMBL29505781 | 0.91 | SLC40A1 (0.65) | SLC40A1 | |
| Hydrochloric Acid SCHEMBL18765305 | 0.91 | SLC40A1 (0.65) | SLC40A1 | |
| SCHEMBL25962678 | 0.88 | SLC40A1 (0.60) | SLC40A1ADORA2AADORA1 | |
| SCHEMBL18781926 | 0.86 | SLC40A1 (0.64) | SLC40A1 | |
| SCHEMBL18781716 | 0.86 | SLC40A1 (0.64) | SLC40A1 | |
| SCHEMBL18764730 | 0.81 | SLC40A1 (0.56) | SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-11001579-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-11 | — | — | US | disclosed |
| US-10738041-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2020-08-11 | — | — | US | disclosed |
| US-20190345151-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-11-14 | — | — | US | disclosed |
| US-10364239-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-07-30 | — | — | US | disclosed |
| WO-2017068089-A2 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017068090-A1 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345151-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | SLC40A1 2/4885ADORA2A 2271/4885ADORA1 3652/4885 |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | SLC40A1 2/4885ADORA2A 2271/4885ADORA1 3652/4885 |
| US-10738041-B2 | Ferroportin inhibitors | SLC40A1, HAMP, TFRC | SLC40A1 1/4885ADORA2A 3699/4885ADORA1 3067/4885 |
| US-11066399-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885ADORA2A 2163/4885ADORA1 3582/4885 |
| US-11001579-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885ADORA2A 2163/4885ADORA1 3582/4885 |
| US-10364239-B2 | Ferroportin inhibitors | HAMP, SLC40A1, HMOX1 | SLC40A1 2/4885ADORA2A 1083/4885ADORA1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.